Dr Pellini on the Use of ctDNA Monitoring After Chemoimmunotherapy Induction in NSCLC
June 29th 2023
Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.